ERBB2 and breast cancer: Choi et al. have indicated that CDK12 drives the development of HER2-positive breast cancer via affecting WNT (Wingless-Integrated) and IRS1 (insulin receptor substrate-1)-ErbB (epidermal growth factor receptor)-PI3K (phosphatidylinositol-3-kinase) signaling [59].